Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy
Sponsor: GTx
A PHASE2 clinical study on Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by GTx and has accumulated 8 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jan 2021 — Apr 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GTx
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boston, United States
- • Lawrence, United States
- • Miami, United States
- • Peoria, United States